Metabolic alterations and chronic hepatitis C: Treatment strategies

Expert Opinion on Pharmacotherapy

Volumn 12, Issue 14, 2011, Pages 2215-2234

  Adinolfi, Luigi E ^a   Restivo, Luciano ^a   Zampino, Rosa ^a   Lonardo, Amedeo ^b   Loria, Paola ^b  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

HCV; insulin resistance; metabolic syndrome; metformin; obesity; pioglitazone; statins; steatosis

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADIPONECTIN; ALPHA2B INTERFERON; ALPHA2B INTERFERON PLUS RIBAVIRIN; ANTILIPEMIC AGENT; ANTIVIRUS AGENT; ATORVASTATIN; CHOLESTEROL; DANOPREVIR; FLUINDOSTATIN; GLUCOSE; GLUCOSE TRANSPORTER 4; INSULIN SENSITIZING AGENT; INTERFERON; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN; PEGINTERFERON; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B PLUS RIBAVIRIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PIOGLITAZONE; RIBAVIRIN; SARTAN DERIVATIVE; SIMVASTATIN; SUPPRESSOR OF CYTOKINE SIGNALING 3; TUMOR NECROSIS FACTOR ALPHA; VERY LOW DENSITY LIPOPROTEIN;

ADD ON THERAPY; ADJUVANT THERAPY; AFRICAN AMERICAN; ALCOHOL CONSUMPTION; ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; ASIAN; ATHEROSCLEROSIS; BODY MASS; CAUCASIAN; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL SYNTHESIS; COHORT ANALYSIS; COMPARATIVE STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE COURSE; DISORDERS OF CARBOHYDRATE METABOLISM; DNA POLYMORPHISM; DOWN REGULATION; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; EGYPT; ERADICATION THERAPY; FATTY ACID BLOOD LEVEL; FATTY ACID OXIDATION; FATTY ACID SYNTHESIS; FATTY LIVER; FOLLOW UP; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; GLUCOSE METABOLISM; GLUCOSE UTILIZATION; GROUPS BY AGE; HEALTH CARE QUALITY; HEPATIC ENCEPHALOPATHY; HEPATITIS; HEPATITIS C; HEPATITIS C VIRUS; HEPATITIS C-ASSOCIATED DYSMETABOLIC SYNDROME; HOMEOSTASIS; HUMAN; HYPERCHOLESTEROLEMIA; HYPERINSULINEMIA; HYPERTENSION; HYPOBETALIPOPROTEINEMIA; IMPAIRED GLUCOSE TOLERANCE; IN VITRO STUDY; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID METABOLISM; LIPID STORAGE; LIPOGENESIS; LIPOLYSIS; LIVER BIOPSY; LIVER CELL; LIVER CELL CARCINOMA; LIVER FIBROSIS; LIVER INJURY; LOW CALORY DIET; METABOLIC SYNDROME X; METABOLISM; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; OBESITY; OBSERVATIONAL METHOD; OBSERVATIONAL STUDY; ORAL GLUCOSE TOLERANCE TEST; OUTCOME ASSESSMENT; PHYSICAL ACTIVITY; PROSPECTIVE STUDY; PROTEIN ASSEMBLY; PROTEIN EXPRESSION; PROTEIN INTERACTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; REVIEW; RISK FACTOR; SEX DIFFERENCE; SPECIFICALLY TARGETED ANTIVIRAL THERAPIES FOR HEPATITIS C; STEATOSIS; SUSTAINED VIROLOGICAL RESPONSE; THROMBOCYTE COUNT; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VIRAL CLEARANCE; VIRAL PHENOMENA AND FUNCTIONS; VIRUS LOAD; VIRUS REPLICATION; WEIGHT REDUCTION;

ANTIVIRAL AGENTS; BODY WEIGHT; CHOLESTEROL; CLINICAL TRIALS AS TOPIC; DRUG THERAPY, COMBINATION; HEPATITIS C, CHRONIC; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INTERFERON-ALPHA; METABOLIC SYNDROME X; POLYETHYLENE GLYCOLS; PREVALENCE; RECOMBINANT PROTEINS; RIBAVIRIN; TREATMENT OUTCOME; VIRAL LOAD;

EID: 80052620533     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2011.597742     Document Type: Review

References (120)

1. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005;365:1415-28 (Pubitemid 40523737)
2. Lonardo A, Caldwell S, Loria P. Clinical physiology of NAFLD: a critical overview of pathogenesis and treatment. Exp Rev Endocrinol Metab 2010;5:403-23
3. Marchesini G, Brizi M, Bianchi G, et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001;50:1844-50 (Pubitemid 33641605)
4. Adinolfi LE, Gambardella M, Andreana A, et al. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001;33:1358-64 (Pubitemid 32496971)
5. Lonardo A, Adinolfi LE, Loria L, et al. Steatosis and HCV: mechanisms and significance for hepatic and extrahepatic disease. Gastroenterology 2004;126:586-97 (Pubitemid 38182315)
6. Lonardo A, Loria P, Adinolfi LE, et al. Hepatitis C and steatosis. A reappraisal. J Viral Hepat 2006;13:73-80
7. Romero-Gomez M, Insulin resistance and hepatitis C. World J Gastroenterol. 2006;12:7075-80 (Pubitemid 44890634)
8. Hourigan LF, MacDonald GA, Purdie D, et al. Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. Hepatology 1999;29:1215-19 (Pubitemid 29168757)
9. Adinolfi LE. Hepatitis C and fatty liver. In: Negro F. editor. Hot topics in viral hepatitis, Hepatitis C and metabolism. 2nd edition. FB Communication; Modena: 2006. p. 21-9
10. Sanyal AJ. Role of insulin resistance and hepatic steatosis in the progression of fibrosis and response to treatment in hepatitis C. Liver Int 2011;31(S1):23-8
11. Charlton MR, Pockros PJ, Harrison SA. Impact of obesity on treatment of chronic hepatitis C. Hepatology 2006;43:1177-86 (Pubitemid 43980094)
12. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005;5:558-67 (Pubitemid 41196755)
13. Lavanchy D. The global burden of hepatitis C. Liver Int 2009;29(Suppl 1):74-81
14. Afdhal NH. The natural history of hepatitis C. Semin Liver Dis 2004;24(Suppl 2):3-8 (Pubitemid 39180700)
15. Craxi A, Pawlotsky JM, Wedemeyer H, et al. EASL clinical practice guidelines: management of hepatitis C virus infection. J Hepatol 2011;55: In press
16. Romero-Gomez M, Del Mar Viloria M, Andrade R, et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 2005;128:636-41 (Pubitemid 40585366)
17. Poustchi H, Negro F, Hui J, et al. Insulin resistance and response to therapy in patients infected with chronic hepatitis C virus genotype 2 and 3. J Hepatol 2008;48:28-34 (Pubitemid 350191982)
18. Grasso A, Alfatti F, de Leo P, et al. Insulin resistance predict rapid virological response in non-diabetic, non-cirrhotic genotupe 1 patients treated with peginterferon alpha-2b plus ribavirin. J Hepatol 2009;51:984-90
19. Kapadia SB, Chiari FB. Hepatitis C virus RNA replication is regulated by host geranylgeranylation and fatty acids. Proc Natl Acad Sci USA 2005;102:2561-6 (Pubitemid 40279416)
20. Shavinskaya A, Boulant S, Penin F, et al. The lipid droplet binding domain of hepatitis C virus core protein is a major determinant for efficient virus assembly. J Biol Chem 2007;282:37158-69
21. Sheikh MY, Choi J, Qadri I, et al. Hepatitis C infection: molecular patways to metabolic syndrome. Hepatology 2008;47:2127-33 (Pubitemid 351945577)
22. Weinman SA, Belalcazar LM. Hepatitis C: a metabolic liver disease. Gastroenterology 2004;126:917-19
23. Cortez-Pinto H. Concluding remarks: metabolic syndrome, liver and HCV. Aliment Pharmacol Ther 2005;22:S83-5
24. Koike K. Hepatitis C as a metabolic disease: implication for the pathogenesis of NASH. Hepatol Res 2005;33:145-50 (Pubitemid 41799793)
25. Lonardo A, Loria P, Carulli N. Dysmetabolic changes associated with HCV: a distinct syndrome? ntern Emerg Med 2008;3:99-108
26. Lonardo A, Loria P. The hepatitis C virus-associated dysmetabolic syndrome. Hepatology 2008;48:1018-19
27. Shaheen M, Echeverry D, Oblad MG, et al. Hepatitis C, metabolic syndrome, and inflammatory markers: results from the Third National Health and Nutrition Examination Survey (NHANES III).Diabetes Res Clin Pract 2007;75:320-6 (Pubitemid 46074212)
28. Hanouneh IA, Feldstein AE, Lopez R, et al. Clinical significance of metabolic syndrome in the setting of chronic hepatitis C virus infection. Clin Gastroenterol Hepatol 2008;6:584-9 (Pubitemid 351609456)
29. Sanyal AJ, Contos MJ, Sterling RK, et al. Nonalcoholic fatty liver disease in patients with hepatitis C is associated with features of the metabolic syndrome. Am J Gastroenterol 2003;98:2064-71 (Pubitemid 37185807)
30. Persico M, Capasso M, Persico E, et al. Suppressor of cytokine signaling 3 (SOCS3) expression and hepatitis C virus-related chronic hepatitis: insulin resistance and response to antiviral therapy. Hepatology 2007;46:1009-15 (Pubitemid 350144765)
31. Svegliati-Baroni G, Bugianesi E, Bouserhal T, et al. Post-load insulin resistance is an independent predictor of hepatic fibrosis in virus C chronic hepatitis and in non-alcoholic liver disease. Gut 2007;56:1296-301 (Pubitemid 47300433)
32. Targher G, Bertolini L, Padovani R, et al. Differences and similarities in early atherosclerosis between patients with non-alcoholic steatohepatitis and chronic hepatitis B and C. J Hepatol 2007;46:1126-32 (Pubitemid 46669732)
33. Tsochatzis E, Papatheodoridis GV, Manesis EK, et al. Metabolic syndrome is associated with severe fibrosis in chronic viral hepatitis and non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2008;27:80-9 (Pubitemid 350212623)
34. Lonardo A, Ballestri S, Adinolfi LE, et al. Hepatitis C virus-infected patients are 'spared' from the metabolic syndrome but not from insulin resistance. A comparative study of nonalcoholic fatty liver disease and hepatitis C virus-related steatosis. Can J Gastroenterol 2009;23:273-8
35. Hui JM, Sud A, Farrell GC, et al. Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression. Gastroenterology 2003;125:1695-704 (Pubitemid 37500434)
36. Leandro G, Mangia A, Hui J, et al. Steatosis is independently associated with hepatic inflammation and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data (the HCV MAID Study).Gastroenterology 2006;130:1636-42
37. Adinolfi LE, Utili R, Ruggiero G. Body composition and hepatic steatosis as precursors of fibrosis in chronic hepatitis C patients. Hepatology 1999;30:1530-1
38. Mirandola S, Realdon S, Iqbal J, et al. Liver microsomal triglyceride transfer protein is involved in hepatitis C liver steatosis. Gastroenterology 2006;130:1661-9 (Pubitemid 43668848)
39. Shintani Y, Fujie H, Miyoshi H, et al. Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology 2004;126:840-8 (Pubitemid 38298332)
40. Fartoux L, Poujol-Robert A, Guechot J, et al. Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C. Gut 2005;54:1003-8 (Pubitemid 40873917)
41. Lonardo A, Adinolfi LE, Loria P. Mechanisms of hepatitis C virus-induced fatty liver disease. In: Negro F. editor. Hot topic in viral hepatitis. FB Communication; Modena: 2009. p. 22-7
42. Perumalswami P, Kleiner DE, Lutchman G, et al. Steatosis and progression of fibrosis in untreated patients with chronic hepatitis C infection. Hepatology 2006;43:780-7
43. Poynard T, Ratziu V, McHutchison J, et al. Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology 2003;38:75-85 (Pubitemid 36775798)
44. Patton HM, Patel K, Behling C, et al. The impact of steatosis on disease preogression and early and sustained treatment response in chronic hepatitis C patients. J Hepatol 2004;40:484-90 (Pubitemid 38230851)
45. Westin J, Lagging M, Dhillon AP, et al. Impact of hepatic steatosis on viral kinetics and treatment outcome during antiviral treatment of chronic HCV infection. J Viral Hepat 2007;14:29-35 (Pubitemid 46012358)
46. Shah SR, Patel K, Marcellin P, et al. Steatosis is an independent predictor of relapse following rapid virologic response in patients with genotype 3. Clin Gastroenterol Hepatol 13 May 2011 [Epub ahead of print]
47. Zekry A, Mchctchison JG, Diel AM. Insulin resistance and steatosis in hepatitis C infection. Gut 2005;54:903-6 (Pubitemid 40873898)
48. Vidali M, Tripodi MF, Ivaldi A, et al. Interplay between oxidative stress and hepatic steatosis in the progression of chronic hepatitis C. J Hepatol 2008;48:399-406
49. Lo Iacono O, Venezia G, Petta S, et al. The impact of insulin resistance, serum adipocytokines and visceral obesity on steatosis and fibrosis in patients with chronic hepatitis C. Aliment Pharmacol Ther 2007;25:1181-91 (Pubitemid 46650297)
50. Valenti L, Al-Serri A, Daly AK, et al. Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. Hepatology 2010;51:1209-17
51. Valenti L, Rumi M, Galmozzi E, et al. Patatin-like phospholipase domain-containing 3 I148M polymorphism, steatosis, and liver damage in chronic hepatitis C. Hepatology 2011;53:791-9
52. Moucari R, Asselah T, Cazals-Hatem D, et al. Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis. Gastroenterology 2008;134:416-23 (Pubitemid 351181308)
53. Pazienza V, Clement S, Pugnale P, et al. The hepatitis C virus core protein of genotypes 3a and 1b downregulates insulin receptor substrate 1 through genotype-specific mechanisms. Hepatology 2007;45:1164-71 (Pubitemid 46775778)
54. Kawaguchi T, Yoshida T, Harada M, et al. Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3. Am J Pathol 2004;165:1499-508 (Pubitemid 39435150)
55. Walsh MJ, Jonsson JR, Richardson MM, et al. Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1. Gut 2006;55:529-35
56. Weyer C, Funahashi T, Tanaka S, et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001;86:1930-5 (Pubitemid 32472900)
57. Durante-Mangoni E, Zampino R, Marrone A, et al. Hepatic steatosis and insulin resistance are associated with serum imbalance of adiponectin/tumour necrosis factor-alpha in chronic hepatitis C patients. Aliment Pharmacol Ther 2006;24:1349-57 (Pubitemid 44571565)
58. Bressler BL, Guindi M, Tomlinson G, et al. High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Hepatology 2003;38:639-44 (Pubitemid 37052150)
59. Lonardo A, Adinolfi LE, Petta S, et al. Hepatitis C and diabetes: the inevitable coincidence? Expert Rev Anti Infect Ther 2009;7:293-308
60. Petta S, Camma C, Marco VD, et al. Insulin resistance and diabetes increase fibrosis in the liver of patients with genotype 1 HCV infection. Am J Gastroenterol 2008;103:1136-44 (Pubitemid 351677995)
61. Sigal SH, Stanca CM, Kontorinis N, et al. Diabetes mellitus is associated with hepatic encephalopathy in patients with HCV cirrhosis. Am J Gastroenterol 2006;101:1490-6 (Pubitemid 43980621)
62. Nshida T, Tsuji S, Tsujii M, et al. Oral glucose tolerance test predicts prognosis of patients with liver cirrhosis. Am J Gastoenterol 2006;101:70-5 (Pubitemid 43381711)
63. D'Souza R, Sabin CA, Foster GR. Insulin resistance plays a significant role in liver fibrosis in chronic hepatitis C and in the response to antiviral therapy. Am J Gastroenterol 2005;100:1509-15 (Pubitemid 41032355)
64. Kwon SY, Kim SS, Kwon OS, et al. Prognostic significance of glycemic control in patients with HBV and HCV-related cirrhosis and diabetes mellitus. Diabet Med 2005;22:1530-5 (Pubitemid 41641160)
65. Romero-Gomez M. Insulin resistance and sustained virological response in hepatitis C: from bench to bedside. Liver Int 2011;31:1-3
66. Eslam M, Aparcero R, Kawaguchi T, et al. Meta-analysis: insulin resistance and sustained virological response in hepatitis C. Aliment Pharmacol Ther 29 May 2011 [Epub ahead of print] Doi: 10.1111/ j.1365-2036.2011.04716.x; PMID: 21623851
67. Lonardo A, Lombardini S, Scaglioni F, et al. Hepatic steatosis and insulin resistance: does etiology make a difference? J Hepatol 2006;44:190-6 (Pubitemid 41772534)
68. Hickman IJ, Jonsson JR, Prins JB, et al. Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life. Gut 2004;53:413-19 (Pubitemid 38241340)
69. Tarantino G, Conca P, Ariello M, et al. Does a lower insulin resistance affect antiviral therapy response in patients suffering from HCV related chronic hepatitis? Gut 2006;55:585-6
70. Harrison SA. Liver disease in patients with diabetes mellitus. J Clin Gastroenterol 2006;40:68-76 (Pubitemid 44378080)
71. Belfort R, Harrison SA, Brown K, et al. A placebo controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006;355:2297-307 (Pubitemid 44837778)
72. Negro F; INSPIRED-HCV Study Group. Correction of insulin resistance in chronic hepatitis C patients not responding to the standard of care: more questions than answers. J Hepatol 2009;50:1271-2
73. Khattab M, Emad M, Abdelaleem A, et al. Pioglitazone improves virological response to peginterferon alpha-2b/ ribavirin combination therapy in hepatitis C genotype 4 patients with insulin resistance. Liver Int 2010;30:447-54
74. Romero-Gomez M, Diago M, Andrade RJ, et al. Spanish Treatment of Resistance to Insulin in Hepatitis C Genotype 1 Group. Treatment of insulin resistance with metformin in na've genotype 1 chronic hepatitis C patients receiving peginterferon alfa-2a plus ribavirin. Hepatology 2009;50:702-8
75. Villa E, Karampatou A, Camma C, et al. Early menopause is associated with lack of response to antiviral therapy in women with chronic hepatitis C. Gastroenterology 2011;140:818-29
76. Moucari R, Forestier N, Larrey D, et al. Danoprevir, an HCV NS3/4A protease inhibitor, improves insulin sensitivity in patients with genotype 1 chronic hepatitis C. Gut 2010;59:1694-8
77. Pawlotski JM. The results of phase III clinical trials with telaprevir and boceprevir presented at the liver meeting 2010: a new standard of care for hepatitis C virus genotype 1 infection, but with issue still pending. Gastroenterology 2011;140:746-54
78. Jackel-Cram C, Babiuk L, Liu Q. Up-regulation of fatty acid synthase promoter by hepatitis C virus core protein: genotype-3a core has a stronger effect than genotype-1b core. J Hepatol 2007;46:999-1008 (Pubitemid 46669729)
79. Negro F, Sanyal AJ. Hepatitis C virus, steatosis and lipid abnormalities: clinical and pathogenic data. Liver Int 2009;29:26-37
80. Hofer H, Bankl HC, Wrba F, et al. Hepatocellular fat accumulation and low serum cholesterol in patients infected with HCV-3a. Am J Gastroenterol 2002;97:2880-5 (Pubitemid 35265443)
81. Ramcharran D, Wahed AS, Conjeevaram HS, et al. Associations between serum lipids and hepatitis C antiviral treatment efficacy. Hepatology 2010;52:854-63
82. Economou M, Milionis H, Filis A, et al. Baseline cholesterol is associated with the response to antiviral therapy in chronic hepatitis C. J Gastroenterol Hepatol 2008;23:586-91 (Pubitemid 351501138)
83. Chisari FV. Unscrambling hepatitis C virus host interaction. Nature 2005;1436:930-2 (Pubitemid 41191667)
84. Wang C, Gale M Jr, Keller BCM, et al. Identification of FBL2 as a geranylgeranylated cellular protein required for hepatitis C virus replication. Mol Cell 2005;18:425-34 (Pubitemid 40704757)
85. Miyoshi H, Moriya K, Tsutsumi T, et al. Pathogenesis of lipid metabolism disorder in hepatitis C: polyunsaturated fatty acids counteract lipid alterations induced by the core protein. J Hepatol 2011;54:432-8
86. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009;461:798-801
87. Suppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009;41:1100-4
88. McCarthy JJ, Li JH, Thompson AJ, et al. Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin. Gastroenterology 2010;138:2307-14
89. Li JH, Lao XQ, Tillmann HL, et al. Interferon-lambada genotype and low serum low-density lipoprotein cholesterol levels in patients with chronic hepatitis C infection. Hepatology 2010;51:1904-11
90. Ikeda M, Abe K, Yamada M, et al. Different anti-HCV profiles of statin and their potential for combination therapy with interferon. Hepatology 2006;44:117-25 (Pubitemid 44049145)
91. O'Leary JG, Chan JL, McMahon CM. Atorvastatin does not exhibit antiviral activity against HCV at conventional doses: a pilot clinical trial. Hepatology 2007;45:895-8 (Pubitemid 46631558)
92. Bader T, Fazili J, Madhoun M, et al. Fluvastatin inhibits hepatitis C replication in humans. Am J Gastroenterol 2008;103:1383-9 (Pubitemid 351813920)
93. Harrison SA, Rossaro L, Hu KQ, et al. Serum cholesterol and statin use predict virological response to peginterferon and ribavirin therapy. Hepatology 2010;52:864-74
94. Rao GA, Pandya PK. Statin therapy improves sustained virologic response among diabetic patients with chronic hepatitis C. Gastroenterology 2011;140:144-52
95. Sezaki H, Suzuki F, Akuta N, et al. An open pilot study exploring the efficacy of fluvastatin, pegylated interferon and ribavirin in patients with hepatitis C virus genotype 1b in high viral loads. Intervirology 2009;52:43-8
96. Georgescu EF, Streba L, Teodorescu R, et al. Potential enhancement of both early (EVR) and sustained (SVR) virological response by fluvastatin in chronic hepatitis C treated with standard pegIFN-ribavirin therapy. A pilot study [abstract 10]. J Hepatol 2011;54(Suppl 1):24
97. Ishizaka N, Ishizaka Y, Takahashi E, et al. Association between hepatitis C virus seropositivity, carotid-artery plaque, and intima-media thickening. Lancet 2002;359:133-5 (Pubitemid 34112545)
98. Butt AA, Xiaoqiang W, Budoff M, et al. Hepatitis C virus infection and the risk of coronary disease. Clin Infect Dis 2009;49:225-32
99. Adinolfi LE, Florio A, Zampino R, et al. Chronic hepatitis C patients with steatosis are at high risk to develop atherosclerosis [book abstracts: 81]. Presented at the EASL Special Conference: NAFLD/NASH and Related Metabolic Disease, 24 - 26 September 2009, Bologna, Italy
100. Yokohama S, Yoneda M, Haneda M, et al. Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology 2004;40:1222-5 (Pubitemid 39425579)
101. Lecube A, Hernandez C, Simo R, et al. Glucose abnormalities are an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Am J Gastroenterol 2007;102:2189-95 (Pubitemid 47493841)
102. Konishi I, Horiike N, Hiasa Y, et al. Diabetes mellitus reduces the therapeutic effectiveness of interferon-alpha2b plus ribavirin therapy in patients with chronic hepatitis C. Hepatol Res 2007;37:331-6 (Pubitemid 46605417)
103. Chu CJ, Lee SD, Hung TH, et al. Insulin resistance is a major determinate of sustained virological response in genotype 1 chronic hepatitis C patients receiving peginterferon alpha-2b plus ribavirin. Aliment Pharmacol Ther 2009;29:46-54
104. Dai CY, Huang JF, Hsieh MY, et al. Insulin resistance predicts response to peginterferon-alpha/ribavirin combination therapy in chronic hepatitis C patients. J Hepatol 2009;50:712-18
105. Grasso A, Malfatti F, De Leo P, et al. Insulin resistance predicts rapid virological response in non-diabetic, noncirrhotic genotype 1 HCV patients treated with peginterferon alpha-2b plus ribavirin. Hepatol 2009;51:984-90
106. Moucari R, Ripault MP, Martinot-Peignoux M, et al. Insulin resistance and geographical origin: major predictors of liver fibrosis and response to peginterferon and ribavirin in HCV-4. Gut 2009;58:1662-9
107. Elgouhari HM, Zein CO, Hanouneh I, et al. Diabetes mellitus is associated with impaired response to antiviral therapy in chronic hepatitis C infection. Dig Dis Sci 2009;54:2699-705
108. Neumann AU, Bain VG, Yoshida EM, et al. Early prediction of sustained virological response at day 3 of treatment with albinterferon-alpha-2b patients with genotype 2/3 chronic hepatitis C. Liver Int 2009;29:1350-5
109. Khattab M, Eslam M, Sharwae MA, et al. Insulin resistance predicts rapid virologic response to peginterferon/ ribavirin combination therapy in hepatitis C genotype 4 patients. Am J Gastroenterol 2010;105:1970-7
110. Bortoletto G, Scribano L, Realdon S, et al. Hyperinsulinaemia reduces the 24-h virological response to PEGinterferon therapy in patients with chronic hepatitis C and insulin resistance. J Viral Hepat 2010;17:475-80
111. Mizuta T, Kawaguchi Y, Eguchi Y, et al. Whole-body insulin sensitivity index is a highly specific predictive marker for virological response to peginterferon plus ribavirin therapy in chronic hepatitis C patients with genotype 1b and high viral load. Dig Dis Sci 2010;55:183-9
112. Conjeevaram HS, Wahed AS, Afdhal N, et al. Changes in insulin sensitivity and body weight during and after peginterferon and ribavirin therapy for hepatitis C. Gastroenterology 2011;140:469-77
113. Fattovich G, Covolo L, Pasino M, et al. The homeostasis model assessment of the insulin resistance score is not predictive of a sustained virological response in chronic hepatitis C patients. Liver Int 2011;31:66-74
114. Simo R, Lecube A, Genesca J, et al. Sustained virological response correlates with reduction in the incidence of glucose abnormalities in patients with chronic hepatitis C virus infection. Diabetes Care 2006;29:2462-6 (Pubitemid 44912253)
115. Backus LI, Boothroyd DB, Phillips BR, et al. Predictors of response of US veterans to treatment for the hepatitis C virus. Hepatology 2007;46:37-47 (Pubitemid 47171919)
116. Romero-Gomez M, Fernandez-Rodriguez CM, Andrade RJ, et al. Effect of sustained virological response to treatment on the incidence of abnormal glucose values in chronic hepatitis C. J Hepatol 2008;48:721-7
117. Giordanino C, Bugianesi E, Smedile A, et al. Incidence of type 2 dibetes mellitus and glucose abnormalities in patients with chronic hepatitis C infection by response to treatment: results of a cohort study. Am J Gastroenterol 2008;103:2481-7
118. Arase Y, Suzuki F, Suzuki Y, et al. Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C. Hepatology 2009;49:739-44
119. Petta S, Camma C, Di Marco V, et al. Time course of insulin resistance during antiviral therapy in non-diabetic, noncirrhotic patients with genotype 1 HCV infection. Antivir Ther 2009;14:631-9
120. Kim HJ, Park JH, Park DL, et al. Clearance of HCV by combination therapy of pegylated interferon alpha-2a and ribavirin improves insulin resistance. Gut Liver 2009;3:108-15